Naito Akira, Tanabe Nobuhiro, Jujo Takayuki, Shigeta Ayako, Sugiura Toshihiko, Sakao Seiichiro, Ishida Keiichi, Tatsumi Koichiro
Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba 260-8670, Japan.
Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba 260-8670, Japan; Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba 260-8670, Japan.
PLoS One. 2014 Nov 20;9(11):e113086. doi: 10.1371/journal.pone.0113086. eCollection 2014.
Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers.
Plasma PTX3 and brain natriuretic peptide (BNP) levels were measured in 70 patients with CTEPH at their first diagnostic right heart catheterization (CTEPH group) and in 20 patients with clinically stable PTE more than three months after the acute episode (control group). The levels of plasma C-reactive protein (CRP) and heart-type fatty acid-binding protein (H-FABP) were also analyzed to compare the diagnostic ability of these biomarkers.
The mean level of PTX3 (ng/mL) was significantly higher in the CTEPH group than in the control group (5.51±4.53 versus 2.01±0.96, respectively), and PTX3 levels had mild negative correlation with cardiac output. BNP levels were also higher in the CTEPH group and better correlated with pulmonary hemodynamics than PTX3. However, a receiver operating characteristic (ROC) curve showed PTX3 levels were better for detecting CTEPH, and could detect CTEPH patients with less severe pulmonary hemodynamics and low plasma BNP levels. There was no significant increase in CRP and H-FABP levels in the CTEPH patients.
Plasma PTX3 level was the most sensitive biomarker of CTEPH. Although plasma PTX3 levels did not correlate with the severity of the pulmonary hemodynamics compared to BNP, high levels in clinically stable patients following PTE should prompt a further work-up for CTEPH, which may lead to an early diagnosis.
五聚体3(PTX3)是一种蛋白质,对先天性免疫、血管生成和血管重塑具有多方面影响,可能是急性心肌梗死、心力衰竭、血管炎的疾病标志物。此外,PTX3已被认为是肺动脉高压的生物标志物,然而在慢性血栓栓塞性肺动脉高压(CTEPH)中是否如此仍不清楚。因此,我们研究了与其他生物标志物相比,PTX3是否会成为检测CTEPH并与稳定型肺血栓栓塞症(PTE)相鉴别的有用生物标志物。
在70例首次诊断为CTEPH的患者进行右心导管检查时(CTEPH组)以及20例急性发作后三个月以上临床稳定的PTE患者(对照组)中,测量血浆PTX3和脑钠肽(BNP)水平。还分析了血浆C反应蛋白(CRP)和心脏型脂肪酸结合蛋白(H-FABP)水平,以比较这些生物标志物的诊断能力。
CTEPH组的PTX3平均水平(ng/mL)显著高于对照组(分别为5.51±4.53和2.01±0.96),且PTX3水平与心输出量呈轻度负相关。CTEPH组的BNP水平也更高,并且与肺血流动力学的相关性比PTX3更好。然而,受试者工作特征(ROC)曲线显示PTX3水平对检测CTEPH更有效,并且可以检测出肺血流动力学不太严重和血浆BNP水平较低的CTEPH患者。CTEPH患者的CRP和H-FABP水平没有显著升高。
血浆PTX3水平是CTEPH最敏感的生物标志物。尽管与BNP相比,血浆PTX3水平与肺血流动力学的严重程度无关,但PTE后临床稳定患者的高水平应促使进一步检查CTEPH,这可能导致早期诊断。